BioCentury
ARTICLE | Company News

Management tracks: Takeda’s Plump becomes president of R&D

February 8, 2019 10:55 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) Andrew Plump has become president of R&D, according to the pharma's website. He was Takeda's CMO and CSO since 2015. Wolfram Nothaft, former head of global clinical development at Shire plc is now Takeda's CMO. Takeda completed its acquisition of Shire in January. The company did not respond to inquiries.

Seres Therapeutics Inc. (NASDAQ:MCRB) said EVP and CSO David Cook will no longer be a full-time employee. EVP and Head of Discovery and Microbiome R&D Matthew Henn will succeed Cook as CSO. Cook will provide consulting services, with a focus on immuno-oncology...